利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.028 秒)

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    1.
    发明申请
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 审中-公开
    包含EPOTHILONES及其药物用途的组合

    公开(公告)号：US20110033458A1

    公开(公告)日：2011-02-10

    申请号：US12908533

    申请日：2010-10-20

    申请人： John Arthur Hohneker ,  Julie Ann Miller ,  John David Rothermel ,  Markus Wartmann

    发明人： John Arthur Hohneker ,  Julie Ann Miller ,  John David Rothermel ,  Markus Wartmann

    IPC分类号： A61K39/395 ,  A61K31/427 ,  A61P35/00

    CPC分类号： C07K16/3015 ,  A61K31/426 ,  A61K31/427 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07D417/06 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosylmethionine decarboxylase inhibitors; and (c) an epothilone derivative of formula I and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

    摘要翻译： 本发明涉及药物组合，其包含（a）HER-1或HER-2抗体或（b）至少一种抗肿瘤剂，其选自芳香酶抑制剂，抗雌激素，拓扑异构酶I抑制剂，拓扑异构酶II抑制剂， 微管活性剂，蛋白激酶C抑制剂，抗血管生成化合物，促性腺激素激动剂，抗雄激素，组蛋白脱乙酰酶抑制剂和S-腺苷甲硫氨酸脱羧酶抑制剂; 和（c）式I的埃坡霉素衍生物和任选的至少一种用于同时，分别或顺序使用的药学上可接受的载体，特别是用于治疗增殖性疾病，特别是实体肿瘤疾病; 包含这种组合的药物组合物; 使用这种组合来制备用于治疗增殖性疾病的药物; 包括作为用于同时，分开或顺序使用的组合制剂的组合的商业包装或产品; 以及治疗温血动物，特别是人的方法。

    Combinations comprising epothilones and pharmaceutical uses thereof
    3.
    发明授权
    Combinations comprising epothilones and pharmaceutical uses thereof 失效
    包含埃坡霉素及其药物用途的组合

    公开(公告)号：US08008330B2

    公开(公告)日：2011-08-30

    申请号：US12549947

    申请日：2009-08-28

    申请人： TianLing Chen ,  Diane Greeley ,  John David Rothermel ,  Markus Wartmann ,  Jeanette Marjorie Wood

    发明人： TianLing Chen ,  Diane Greeley ,  John David Rothermel ,  Markus Wartmann ,  Jeanette Marjorie Wood

    IPC分类号： A61K31/427 ,  A61K31/28

    CPC分类号： A61K31/663 ,  A61K31/427 ,  A61K31/502 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

    摘要翻译： 本发明涉及一种组合，其包含（a）二膦酸盐，铂化合物或血管保护性化合物和（b）式I的埃坡霉素衍生物，其中A表示O或NRN，其中RN为氢或低级烷基，R为氢或 低级烷基和Z是O或键，其中活性成分（a）和（b）在每种情况下以游离形式或以药学上可接受的盐和任选的至少一种药学上可接受的载体的形式存在 ，单独或顺序使用，特别是用于延缓进展或治疗增殖性疾病，特别是实体肿瘤疾病; 药物组合物，商业包装或包含这种组合的产品; 使用这种组合来制备用于延缓进展或治疗增殖性疾病的药物以及治疗温血动物的方法。

    Tubulin Mutation Diagnostic
    5.
    发明申请
    Tubulin Mutation Diagnostic 审中-公开
    微管蛋白突变诊断

    公开(公告)号：US20080131884A1

    公开(公告)日：2008-06-05

    申请号：US11718957

    申请日：2005-11-10

    申请人： Kenneth Wayne Culver ,  Markus Wartmann ,  Stan Lilleberg ,  Jian Zhu

    发明人： Kenneth Wayne Culver ,  Markus Wartmann ,  Stan Lilleberg ,  Jian Zhu

    IPC分类号： A61K48/00 ,  A61P43/00 ,  C07H21/04 ,  C07K16/00 ,  C12Q1/68 ,  G01N33/53

    CPC分类号： C12Q1/6883 ,  C07K14/47 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/68 ,  G01N33/6848 ,  G01N2800/52

    摘要： The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the β-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the β-tubulin gene, variants of the β-tubulin protein, nucleic acid molecules and agents which bind to the variant β-tubulin nucleic acid molecules and variant β-tubulin protein, respectively, and kits comprising the same.

    摘要翻译： 本发明涉及通过测定β-微管蛋白基因或蛋白质中一个或多个核苷酸或氨基酸变体的存在来确定受试者对特定治疗剂作出反应的潜力的方法。 还提供了用于治疗对治疗剂有响应的潜能的方法。 为了用于本发明的方法，提供β-微管蛋白基因的变体，β-微管蛋白的变体，结合变体β-微管蛋白核酸分子和变体β-微管蛋白的核酸分子和试剂 ，以及包含其的试剂盒。

    Combinations comprising epothilones and pharmaceutical uses thereof
    6.
    发明授权
    Combinations comprising epothilones and pharmaceutical uses thereof 失效
    包含埃坡霉素及其药物用途的组合

    公开(公告)号：US07612052B2

    公开(公告)日：2009-11-03

    申请号：US12019294

    申请日：2008-01-24

    申请人： John David Rothermel ,  Markus Wartmann ,  Jeanette Marjorie Wood

    发明人： John David Rothermel ,  Markus Wartmann ,  Jeanette Marjorie Wood

    IPC分类号： A61K31/66 ,  A61K31/425 ,  A61K31/28

    CPC分类号： A61K31/663 ,  A61K31/427 ,  A61K31/502 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

    摘要翻译： 本发明涉及一种组合，其包含（a）二膦酸盐，铂化合物或血管保护性化合物和（b）式I的埃坡霉素衍生物，其中A表示O或NRN，其中RN为氢或低级烷基，R为氢或 低级烷基和Z是O或键，其中活性成分（a）和（b）在每种情况下以游离形式或以药学上可接受的盐和任选的至少一种药学上可接受的载体的形式存在 ，单独或顺序使用，特别是用于延缓进展或治疗增殖性疾病，特别是实体肿瘤疾病; 药物组合物，商业包装或包含这种组合的产品; 使用这种组合来制备用于延缓进展或治疗增殖性疾病的药物以及治疗温血动物的方法。